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Abstract
Purpose Immune checkpoint inhibitors (ICI) have shown marked responses in patients with non-small cell lung cancer 
(NSCLC) in clinical trials. However, because such trials comprise cohorts selected based on specific criteria, it is unclear if 
their results represent routine clinical practice.
Methods We examined 155 patients with advanced NSCLC who were administered either nivolumab or pembrolizumab at 
Yonsei Cancer Center, Korea between March 2014 and January 2019. Patient characteristics, EGFR/ALK mutation status, 
metastatic locations, response to ICIs, and adverse events were retrospectively analyzed.
Results The median age was 64 years and 72.9% of patients were male; former or current smokers constituted 67.1% of the 
subjects. Adenocarcinoma was predominant (67.7%), and 50.3% of the patients underwent ≥ 2 previous treatments. Twenty-
three patients (14.8%) were EGFR mutation- or ALK rearrangement-positive. The objective response rate (ORR) was 23.9% 
[95% confidence interval (CI) 17.4–31.4%]; the median progression-free survival (PFS) and overall survival (OS) were 3.06 
(95% CI 1.893–4.21) and 10.25 (95% CI 5.39–15.11) months, respectively. Multivariate analysis identified ECOG perfor-
mance status, EGFR mutation/ALK rearrangement status, liver metastasis and PD-L1 proportion as independent predictors 
of OS. Furthermore, 61.9% of the patients had adverse events of any grade; 38.1% had immune-related adverse events that 
were associated with PFS and OS on multivariate analysis.
Conclusions The real-world ORR, PFS, OS, and adverse event profiles were comparable to previous clinical trials despite 
the patients’ different baseline characteristics. Our findings can aid in establishing effective immunotherapeutic management 
of NSCLC in routine clinical practice.
Keywords Immunotherapy · Non-small cell lung cancer · Real-world setting · PD-1 · Survival
Introduction
Lung cancer is a major cause of cancer-related deaths 
worldwide (Siegel et al. 2017). Non-small cell lung can-
cer (NSCLC) accounts for approximately 85% of all lung 
cancers, of which approximately 70% have non-squamous 
histologies (Herbst et al. 2008; Travis et al. 1995). In 2016, 
a total of 24,267 new cases of lung cancer were reported in 
Korea and 17,399 individuals died of this disease, making 
it the leading cause of cancer-related death in both sexes 
(Mortality table of Korea 2015).
Patients with advanced lung cancer eventually develop 
chemotherapy-resistant disease after treatment with con-
ventional cytotoxic agents, demonstrating the necessity for 
devising other treatment options for refractory NSCLC. 
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More recently, programmed cell death protein 1 (PD-1)/pro-
grammed death-ligand 1 (PD-L1) immune checkpoint inhibi-
tors (ICIs) showed potent activity against metastatic NSCLC 
in subsets of clinical trials (Borghaei et al. 2015; Brahmer 
et al. 2015; Herbst et al. 2016). Some randomized phase III 
trials have reported a statistically significant achievement 
in overall survival (OS) with ICIs over docetaxel in patients 
with platinum-refractory NSCLC: the CheckMate 017 and 
CheckMate 057 trials in patients with squamous and non-
squamous NSCLC, respectively (both tested nivolumab, a 
monoclonal-antibody of PD-1) (Borghaei et al. 2015; Brah-
mer et al. 2015); the Keynote 010 phase II/III trial with pem-
brolizumab, which also interacts to PD-1 (participation was 
restricted to at least 1% PD-L1 expression level on tumor 
cells) (Herbst et al. 2016). To date, the phase III Keynote 
024 and Keynote 042 trials reported that pembrolizumab 
significantly improves the progression-free survival (PFS) 
and OS over standard first-line platinum-based chemother-
apy; these trials comprise patients with at least 50% PD-L1 
and 1% PD-L1 expression in their tumor cells, respectively 
(Lopes et al. 2018; Reck et al. 2016). Based on all these 
trials, PD-1 inhibitors including nivolumab and pembroli-
zumab are now approved as standard anticancer treatments 
for patients with advanced NSCLC.
However, clinical trials have strict and complex enroll-
ment criteria (Garcia et al. 2017). The line of therapy for 
patient eligibility is usually pre-determined in trials compar-
ing the efficacy of novel investigational products to previ-
ous chemotherapies. Thus, the outcomes of these trials do 
not necessarily represent real-world patients. In particular, 
there is limited evidence regarding the real-world efficacy of 
immunotherapy and related clinical findings in patients who 
are unsuitable for clinical trials or else are categorized into 
specific subgroups, including those with poor performance 
status (PS), those with EGFR mutations/ALK rearrange-
ments, and those of Asian ethnicity (Borghaei et al. 2015; 
Brahmer et al. 2015).
Therefore, we conducted this retrospective analysis of 155 
unselected patients with advanced NSCLC; to our knowl-
edge, this study is the largest of its kind performed in Korea. 
We posited that identifying the clinical characteristics that 
influence the efficacy of immunotherapy in a real-world set-
ting would be beneficial for validating previous observations 
and devising an effective immunotherapy strategy in routine 
clinical practice.
Methods
Patients and samples
In total, 155 patients with advanced NSCLC who 
were administered a PD-1 inhibitor (nivolumab or 
pembrolizumab) at Yonsei Cancer center between March 
2014 and January 2019 were enrolled. Clinical data includ-
ing patient characteristics, driver gene mutation status, meta-
static locations, response to immunotherapy, and adverse 
events were retrospectively collected and analyzed. The 
patients were treated with nivolumab at a dose of 3.0 mg/
kg body weight every 2 weeks or pembrolizumab at 200 mg 
fixed dose every 3 weeks (which represent the licensed 
dose and administration method in Korea). This study was 
approved by the institutional review board (IRB no. 4-2016-
0678); the requirement for informed consent was waived.
Assessments
Patients were assessed for treatment response by computed 
tomography (CT). Chest CT and abdominal CT were taken 
every two or three cycles during the treatment. Besides regu-
lar follow-up, additional images were acquired according to 
the physician’s discretion. The clinical response to anti-PD-1 
treatment was evaluated using these images according to the 
Response Evaluation Criteria in Solid Tumors (RECIST), 
version 1.1 (Eisenhauer et al. 2009). The tumor responses 
to anti-PD-1 treatment were defined as follows: complete 
response (CR; the disappearance of all target lesions), partial 
response (PR; 30.0% or more reduction in the sum of the 
diameters of the target lesions), progressive disease (PD; 
20.0% or more increase in the sum of the diameters of the 
target lesions), and stable disease (SD; not in category to 
qualify as PR or PD). To consider the difference between 
RECIST criteria and immune modified-RECIST the patients 
who were assessed as PD had reassessment after 4–8 weeks 
to confirm it. The objective response rate (ORR) was defined 
as the proportion of patients with CR or PR, while the dis-
ease control rate (DCR) was defined as the proportion of 
patients with CR, PR, or SD. PFS was defined as the time 
from the start of anti-PD-1 treatment to disease progression 
or death. OS was defined as time from the start of anti-PD-1 
treatment to death by any cause. Adverse events related to 
anti-PD-1 treatment were stated according to the Common 
Terminology Criteria for Adverse Events, version 4.0 [Com-
mon Terminology Criteria for Adverse Events (CTCAE) 
v4.0 (2018)].
Statistical analysis
The Kaplan–Meier method was used to estimate OS and 
PFS; subgroups were compared using the log-rank test for 
total number of patients. Additional propensity score match-
ing analysis for each clinical characteristic were done to 
reduce the bias due to confounding variables. Univariable 
and multivariable Cox proportional hazard regression mod-
els were adopted to determine hazard ratios with 95% con-
fidence intervals (CIs). Multivariate analysis was performed 
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with adjustment for age, sex, smoking status, number of 
prior treatment lines, mutational status, brain metastasis, 
liver metastasis, and PD-L1 expression level. Additionally, 
due to the time-dependent nature of immune-related adverse 
events (irAEs), we performed 6-week landmark analyses 
including patients who achieved disease control (for PFS; 
n = 111) and those who were alive (for OS; n = 133) at 6 
weeks to determine the association between irAEs and sur-
vival outcomes. Statistical analyses were performed using 
SPSS version 23 (IBM Software, Armonk, NY, USA) and 
GraphPad Prism version 5.00 (GraphPad Software, San 
Diego, CA, USA).
Identification of PD‑L1 expression
In most cases, tumor PD-L1 expression was determined 
immunohistochemically using the PD-L1 22C3 pharmDx 
antibody (Dako North America Inc., Carpinteria, CA, USA) 
or Ventana PD-L1 SP263 antibody (Ventana Medical Sys-
tems, Tucson, AZ, USA) as companion diagnosis. PD-L1 
expression levels in tumor cells were determined by the 
percentage of stained tumor cells in each section, which 
was estimated in increments of 5% except for a 1% value. 
Patients with at least 1% of the tumor cells who were stained 
for PD-L1 were considered positive.
Results
Clinicopathologic characteristics of the study 
population
In total, 155 patients with advanced NSCLC were 
enrolled (Table 1); the majorities were male (72.9) and 
aged ≥ 60 years (68.4%). Most patients had adenocarcinoma 
(67.7%) or squamous carcinoma (30.3%). Twenty-three 
patients (14.8%) had EGFR mutations (n = 22) or ALK rear-
rangement (n = 1), and 99 (63.9%) were identified as PD-L1 
positive. Thirty-four patients (21.9%) had an ECOG per-
formance status score of 2 or higher at the beginning of the 
treatment. As opposed to clinical trials, the lines of adminis-
tered therapies were diverse, as 16 (10.3%), 61 (39.4%), and 
78 (50.3%) of the patients received anti-PD-1 treatment as 
first-line, second-line, or subsequent to second-line therapy, 
respectively. At presentation immediately before immuno-
therapy, the most frequent site of metastasis was the ipsi-
lateral or contralateral lung (71.0%), followed by the brain 
(39.4%), bone (32.9%), and adrenal gland (18.1%). By the 
time of data lock (January 30, 2019), 49 patients (31.6%) 
were alive, 92 (59.4%) had died, and 14 (9.0%) was lost to 
follow-up. The median follow-up duration for the patients 
was 17.0 months.
Treatment outcomes and potential predictors
The treatment outcomes for all patients are shown in S1 
Table. The ORR was 23.9% (n = 37), all based on achiev-
ing PR. Moreover, 35.5% of the patients had SD, 29.7% 
had PD, and 11.0% were not evaluated. The median OS 
Table 1  Baseline characteristics
ECOG PS Eastern Cooperative Oncology Group performance status, 
EGFR epidermal growth factor receptor, ALK anaplastic lymphoma 
kinase
n (%)
Age (years)
 Median (range) 64 (35–85)
 < 60 49 (31.6)
Sex
 Male 113 (72.9)
 Female 42 (27.1)
Histology
 Adenocarcinoma 105 (67.7)
 Squamous 47 (30.3)
 Pleomorphic 2 (1.3)
 Unknown 1 (0.6)
Smoking
 Never 51 (32.9)
 Former smoker 61 (39.4)
 Current smoker 43 (27.7)
EGFR and ALK
 Wild-type (both) 131 (84.5)
 Mutant 23 (14.8) 
(ALK: n = 1)
 Unknown 1 (0.7)
ECOG PS score
 0 23 (14.8)
 1 98 (63.2)
 2 20 (12.9)
 3 14 (9.0)
Prior treatment lines
 0 16 (10.3)
 1 61 (39.4)
 2 32 (20.6)
 3 28 (18.1)
 4 8 (5.2)
 ≥ 5 10 (6.4)
Metastasis present
 Lung ipsilateral 95 (61.3)
 Lung contralateral 79 (51.0)
 Brain 61 (39.4)
 Bone 51 (32.9)
 Adrenal gland 28 (18.1)
 Liver 24 (15.5)
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and PFS were 10.25 months (95% CI 5.39–15.11) and 3.06 
months (95% CI 1.89–4.21), respectively, for all patients 
(Fig. 1).
We further investigated patients stratified by clinico-
pathologic factors. ORRs of patients with PS scores of 0–1 
and 2–4 were 29.8% and 2.9%, respectively; the DCRs of 
these subgroups were 71.9% and 14.7%, respectively. The 
ORRs of patients who were never-smokers, were EGFR 
mutation/ALK-rearrangement-positive, and had ≥ 50% 
PD-L1 expression were 13.7%, 13.0%, and 37.7%, respec-
tively; the corresponding DCRs were 51.0% and 34.7%, 
and 75.4%, respectively.
We next performed PFS and OS analyses of patients 
stratified by the above factors and metastatic lesions. 
Age, sex, and smoking status did not significantly influ-
ence OS and PFS. However, median PFS rates of patients 
with EGFR mutation/ALK rearrangement were signifi-
cantly shorter than those of wild-type patients (1.6 vs. 3.8 
months; P < 0.01) as were OS rates (4.4 vs. 13.5 months; 
P < 0.01). Furthermore, the median PFS of patients with 
50% or more PD-L1-positive cells was 6.0 months, which 
was significantly longer than those with 0–49% PD-
L1-positive cells (2.9 months; P < 0.01); the same was true 
for OS (20.5 vs. 7.8 months, P = 0.021). Other factors that 
showed significant differences were PS score, the presence 
of metastatic lesions (i.e., in the brain and liver), and line 
of therapy. Kaplan–Meier plots are shown in Fig. 2 and 
S1 Fig.
Multivariate analysis identified poor PS, EGFR 
mutation/ALK rearrangement positivity, liver metastasis 
and low PD-L1 expression as independent negative predic-
tors of OS (Table 2).
Brain and liver metastasis response
We also analyzed the treatment outcomes of patients accord-
ing to brain and/or liver metastasis status. Sixty-one patients 
had brain metastasis upon commencing ICI therapy, 41 of 
whom underwent local radiotherapy before or during treat-
ment. Response in the brain was evaluated via magnetic res-
onance imaging during the same global response evaluation 
cycle. The patients’ intracranial ORR and DCR were 16.4% 
(95% CI 8.16–28.10%) and 42.6% (95% CI 30.02–55.92%), 
respectively. The ORR did not differ significantly from 
the global response rate (16.4% vs. 23.9%, P = 0.23), but 
the DCRs were significantly different (42.6% vs. 59.4%, 
P = 0.026). Furthermore, 25 patients had liver metastasis; 
their ORR and DCR were 12.0% (95% CI 2.55–31.22%) and 
32.0% (95% CI 14.95–53.50%), respectively, and only the 
DCR differed significantly from the global response (ORR, 
P = 0.19; DCR, P = 0.011). The treatment responses of each 
region for patients with brain and liver metastases are shown 
in S2 Table.
Adverse events and their association with clinical 
outcomes
The proportion of patients who experienced adverse events 
of any type and grade was 61.9%. The three most com-
mon adverse events were rash (19.4%), decreased appetite 
(12.3%), and fatigue (11.6%); none were grade ≥ 3. The most 
common grade ≥ 3 adverse event was pneumonia (6.5%) fol-
lowed by pneumonitis (3.2%).
Based on the previous studies, we defined irAEs as adverse 
events with a potential immunological basis that require 
Fig. 1  Kaplan–Meier plot for the total population (n = 139). a Overall survival (OS) and b progression-free survival (PFS) from the beginning of 
anti-PD-1 treatment. PD-L1 programmed death-ligand 1
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immunosuppressive or endocrine therapy (Friedman et al. 
2016). We strictly considered only those irAEs that medical 
professionals could recognize objectively via physical exami-
nation or laboratory results; this also helped to reduce bias. 
IrAEs observed in our patients are shown in Table 3. The 
pneumonitis was distinguished from pneumonia by sputum 
culture plus laboratory C-reactive protein (CRP) and procal-
citonin level. Most of patients who were diagnosed as pneu-
monitis had process of multidisciplinary team meeting and/or 
consultation to pulmonologists (S3 Table).
We categorized hypothyroidism, adrenal insufficiency, 
and panhypopituitarism as endocrine irAEs for further 
analysis. The proportion of patients who experienced irAEs 
was 38.1% and 5.16% experienced grade ≥ 3 irAEs. Six-
week landmark analysis showed that the ORR of patients 
with irAEs was higher than in those without, although not 
significantly different [21 of 51 patients (41.2%) vs. 16 of 
60 patients (26.7%); P = 0.11]. However, the development 
of irAEs was significantly associated with longer PFS 
[11.63 months (95% CI 9.21–14.05) vs. 3.27 months (95% 
CI 2.01–4.17); P < 0.001] and OS [24.05 months (95% CI 
NR–NR) vs. 7.39 months (95% CI 3.49–11.29); P < 0.001]. 
Upon further analysis of irAE subtypes, patients with skin 
rash had significantly longer PFS [11.40 months (95% CI 
7.87–14.93) vs. 5.09 months (95% CI 3.53–6.66); P = 0.008] 
and OS [NR (95% CI NR–NR) vs. 11.37 months (95% CI 
5.84–16.89); P = 0.004]. Patients with endocrine irAEs 
had longer PFS [10.22 months (95% CI 6.04–14.39) vs. 
5.09 months (95% CI 3.49–6.70); P = 0.054] and OS [NR 
(95% CI NR–NR) vs. 12.58 months (95% CI 8.02–17.15); 
P = 0.037], although the differences were not significant for 
PFS (Fig. 3).
Multivariate analysis revealed that the presence of any 
irAEs was significantly associated with increased PFS and 
OS based on the 6-week landmark analysis, whereas skin 
irAEs and endocrine irAEs subsets were not. Overall, skin 
and endocrine irAEs were not identified as significant posi-
tive predictive factors, though they showed a tendency as 
such (Table 4).
Additional 12-week and 24-week landmark analysis were 
also done and are shown on online resource (S4 Table and 
S2 Fig.) The result of these analyses showed similar trend as 
6-week landmark but 12-week analysis only showed signifi-
cance between the presence of any irAEs and OS not with 
PFS. 24-week analysis did not show significance and only 
showed similar trends.
Discussion
Currently, the National Clinical Cancer Network and 
American Society of Clinical Oncology guidelines do not 
recommend more than two consecutive lines of cytotoxic 
chemotherapy for advanced NSCLC; intervening or subse-
quent immunotherapy, best supportive care, or participation 
in a clinical trial is otherwise recommended (Rizvi et al. 
2015; Rozenblum et al. 2017). In contrast to chemotherapy 
or tyrosine kinase inhibitors, ICIs have the ability to restore 
a patient’s antitumor immunity, allowing the destruction of 
malignant cells with the potential for a robust and durable 
clinical response (Wang et al. 2014). In the CheckMate 017 
(squamous NSCLC) and CheckMate 057 (non-squamous 
NSCLC) clinical trials for nivolumab, the ORRs were 20.0% 
and 19.0%, median PFS rates were 3.5 and 2.3 months, and 
median OS rates were 9.2 and 12.2 months, respectively 
(Borghaei et al. 2015; Brahmer et al. 2015). The Keynote 
001 study of pembrolizumab for patients with advanced 
NSCLC reported an objective response rate of 19.4%, 
median PFS of 3.7 months, and median OS of 12 months 
(Garon et al. 2015). Hence, immunotherapy has become an 
indispensable option for any line of therapy for advanced 
NSCLC.
The ORR, PFS, and OS in our study (23.9%, 3.06 months, 
and 10.25 months, respectively) were comparable to those 
of the previous studies. Although we enrolled unselected 
patients who were ineligible for the previous trials or par-
ticipated as minor subset cohorts (including those with poor 
PS, EGFR mutations/ALK rearrangements, and brain and 
liver metastases, which are factors known to be indicators 
of unfavorable responses to immunotherapy) (Tamiya et al. 
2018), the clinical outcomes were similar to the previously 
published results. This could be partially explained by higher 
PD-L1 expression (40.5% of patients in our study had PD-L1 
expression levels ≥ 50%; whereas 23.3% of patients exhib-
ited PD-L1 levels ≥ 50% in the Keynote-001 study and 37.2% 
exhibited PD-L1 levels ≥ 10% in the CheckMate-057 study) 
(Borghaei et al. 2015; Garon et al. 2015). Higher PD-L1 
expression is reportedly a favorable predictor of immuno-
therapy efficacy, and levels of this protein are usually higher 
among Asians (Lin et al. 2016; Patel and Kurzrock 2015). 
Furthermore, ethnicity itself could have been a factor, since 
the abovementioned studies comprised mostly Caucasian 
patients, whereas ours were Asian.
Our data indicated that harboring EGFR mutations/ALK 
rearrangements was associated with poorer PFS and OS, 
which was consistent with recent retrospective and prospec-
tive studies (Lee et al. 2017). Preliminary studies suggest 
that sensitivity to ICIs is high in tumors with high somatic 
mutations (Rizvi et al. 2015; Rozenblum et al. 2017). There-
fore, never-smokers and patients with EGFR mutations/ALK 
rearrangements are known to have poorer outcomes because 
of their low mutational burdens, although our study did not 
reveal an association between smoking status and survival 
outcomes. Subgroup analyses of both the CheckMate 057 
(Borghaei et al. 2015) and Keynote 010 (Herbst et al. 2016) 
prospective trials revealed no significant OS differences 
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based on EGFR mutation status. Overall, excluding patients 
with EGFR mutations/ALK rearrangements ought to produce 
a higher response rate to anti-PD-1 immunotherapy in rou-
tine clinical practice.
Our results also suggested that PD-L1 expression lev-
els ≥ 50% were well-correlated with improved PFS and OS 
rates following anti-PD-1 treatment. As PD-L1 expression 
alone is accepted as an imperfect biomarker for predicting 
prognosis, it remains debated whether PD-L1 expression 
levels should be used as a benchmark for prescribing ICIs 
(Herbst et al. 2014; Patel and Kurzrock 2015). However, our 
results imply that determining PD-L1 status can help iden-
tify patients most likely to benefit from anti-PD-1 treatment 
in real-world settings.
The existence of liver or brain metastases at the com-
mencement of immunotherapy was associated with poor PFS 
and OS in our study. Patients with advanced NSCLC who 
have liver or brain metastases and are receiving chemother-
apy or tyrosine kinase inhibitors are known to have poorer 
prognoses than those with metastases in other locations 
(Hoang et al. 2012). There are only few retrospective stud-
ies regarding immunotherapy outcomes and their association 
with metastatic lesions. One such retrospective study showed 
a relationship between the metastatic site and PFS in patients 
with advanced NSCLC who were treated with nivolumab 
(Tamiya et al. 2018), while another found that nivolumab 
was effective against brain metastasis (Gauvain et al. 2018). 
In our study, we revealed not only differences in ORR and 
PFS, but also in OS in patients who received anti-PD-1. This 
supports considering the metastatic lesion site a criterion for 
selecting candidates for immunotherapy.
Finally, our data indicated that the development of cer-
tain irAEs is associated with improved anti-PD-1 treat-
ment efficacy in patients with NSCLC, which is consist-
ent with earlier studies (Suresh et al. 2018; Teraoka et al. 
2017). A previous retrospective study showed that thyroid 
dysfunction irAE is associated with a better prognosis in 
patients with NSCLC (Osorio et al. 2017). Several other 
retrospective studies have demonstrated similar associa-
tions in patients with dermatological irAEs who were 
treated for melanoma and NSCLC with ICIs (Freeman-
Keller et al. 2016; Hasan Ali et al. 2016). Most recently, 
Haratani et al. performed a landmark analysis that revealed 
significant differences in both PFS and OS between 
NSCLC patients with vs. without irAEs [hazard ratios of 
0.525 (95% CI 0.287–0.937); P = 0.03 for PFS and 0.282 
(95% CI 0.101–0.667); P = 0.003 for OS on multivariate 
analysis] (Haratani et al. 2018; Teraoka et al. 2017) Our 
own 6-week landmark analysis revealed significant dif-
ferences in OS and PFS when patients were stratified by 
existence of irAEs, also multivariate analysis confirmed a 
significant difference for PFS and OS. Our study included 
a greater number of covariables than those examined by 
Haratan et al.; we additionally investigated PD-L1 status, 
PS, and liver metastasis (Table 4). Our comprehensive 
landmark analyses suggest that the early onset of irAEs is 
predictive of response or of the durable clinical benefits in 
patients with NSCLC treated with PD-1 inhibitors, thereby 
possibly aiding clinicians in improving immunotherapy 
planning, including whether to switch or cease treatment, 
during the interval before the routine response evaluation.
To the best of our knowledge, ours is one of the largest 
comprehensive retrospective studies of real-world patients 
who were treated with PD-1 inhibitors. Previous retrospec-
tive studies examined real-world situations only partially, 
and their findings were, therefore, confined in scope. For 
example, some studies included only patients who were 
previously treated, while others only considered patients 
who received a single immunotherapy agent. Furthermore, 
due to insufficient follow-up periods, most of the previous 
retrospective studies were unable to determine matured OS 
dates (Fujimoto et al. 2018; Garassino et al. 2018; Kobayashi 
et al. 2018). In contrast, our study comprised near-complete 
results for both efficacy and safety; in addition, it compared 
the outcomes of patients with specific clinical factors and 
adverse events in detail.
In conclusion, our study provided comprehensive clinical 
characteristics and outcomes of patients with NSCLC who 
received anti-PD-1 treatment in Korea. In the context of het-
erogeneous real-world settings, further efforts are required to 
develop efficient therapeutic strategies, ranging from proper 
patient selection to determining the correct timing of admin-
istering immunotherapy.
Fig. 2  Kaplan–Meier plot for the overall survival (OS) stratified by 
clinical factors. a Sex; b liver metastasis; c brain metastasis; d line 
of therapy; e EGFR/ALK mutation status; f PD-L1 expression level 
of 50%. PD-L1 programmed death-ligand 1, EGFR epidermal growth 
factor receptor, ALK anaplastic lymphoma kinase, HR hazard ratio, 
n.s. not significant, UD undetermined
◂
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Table 2  Cox proportional 
hazards regression analysis of 
the effects of clinical factors on 
overall survival
HR hazard ratio, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance sta-
tus (score), PD-L1 programmed death-ligand 1
Category Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Age (< 75 vs. ≥ 75 years) 1.049 0.593–1.854 0.871 0.712 0.337–1.502 0.372
Sex (male vs. female) 1.167 0.748–1.822 0.496 0.527 0.150–1.848 0.317
ECOG PS (0– 1 vs. 2– 3) 6.989 4.391–11.12 < 0.001 7.566 4.008–14.282 < 0.001
Smoking (never vs. current or former) 1.022 0.645–1.620 0.925 0.878 0.258–2.987 0.835
PD-L1 (< 50% vs. ≥50%) 0.631 0.398–0.999 0.049 0.430 0.250–0.741 0.002
Liver metastases (absent vs. present) 2.045 1.228–3.406 0.006 2.388 1.263–4.513 0.007
Brain metastases (absent vs. present) 1.926 1.272–2.917 0.002 1.601 0.935–2.741 0.086
Prior treatment line (≥ 2 vs. <2) 1.777 1.170–2.700 0.007 1.202 0.685–2.109 0.521
EGFR mutation or ALK rearrangement 
(absent vs. present)
2.230 1.352–3.676 0.002 2.711 1.377–5.338 0.0024
Table 3  Treatment-related 
adverse events according to 
category and grade
AE adverse event, ALT alanine aminotransferase, AST aspartate aminotransferase
Adverse events No. of subjects (all 
grades)
Percentage (all 
grades)
No. of subjects 
(grades 3–4)
Percentage 
(grades 3–4)
Any AEs
 Decrease appetite 19 12.3 0 0
 Fatigue 18 11.6 0 0
 Dyspnea 16 10.3 1 0.7
 Pneumonia 15 10.3 10 6.5
 Nausea/vomiting 4 2.6 0 0
 Pyrexia 3 1.9 0 0
 Constipation 3 1.9 0 0
 Edema 2 1.3 0 0
 Neuropathy 1 0.7 0 0
 Infusion reaction 1 0.7 0 0
Immune-related AEs
 Rash 30 19.4 0 0
 Pneumonitis 11 12.2 5 3.2
 Diarrhea 10 6.5 1 0.7
 Hypothyroidism 10 6.5 0 0
 AST/ALT elevation 5 3.2 0 0
 Hemolytic anemia 3 1.9 1 0.7
 Adrenal insufficiency 3 1.9 0 0
 Panhypopituitarism 1 0.7 1 0.7
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Fig. 3  Kaplan–Meier plot with 6-week landmark analysis for the 
overall survival (OS) and progression-free survival (PFS) stratified by 
the presence of irAEs. By any irAEs a OS, b PFS; by skin irAEs c 
OS, d PFS; by endocrine irAEs e OS, f PFS. irAE immune-related 
adverse event, HR hazard ratio, n.s. not significant, UD undetermined
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